CENTRAL LABORATORIES WHITE PAPERS & ARTICLES

• Paper COAs In 2026? It's Not "Cheaper," It's Riskier

  Paper-based assessments add operational and regulatory risk — from poor data quality to delayed insights — quietly threatening timelines, compliance, and trial confidence.

• Medical Device Clinical Trials: Key Considerations For Sponsors And CROs

  Medical device trials must align risk class, regulations, and study design. Strong oversight, data, and proactive safety planning support reliable evidence and market approval.

• A Guide To Medical Coding In Clinical Trials

  Medical coding transforms free-text clinical data into standardized terminology, enabling consistent analysis, safety monitoring, and regulatory review. Clear guidelines and quality control help reduce variability and protect data integrity across the entire clinical trial lifecycle.

• A New Era Of ADC Development Demands A New Kind Of Partner

  Explore how to navigate the evolution of antibody-drug conjugates by mastering AI-driven selection, dose optimization, and new regulatory strategies for earlier-line clinical success.

• Innovating With Generative And Agentic Artificial Intelligence

  Discover how specialized AI is revolutionizing clinical trials by enhancing data quality and operational speed through curated training, human oversight, and objective scientific analysis.